AI-driven De novo Design of Targeted Peptide Radiotracers for Clear Cell Renal Cell Carcinoma (EANM 2026) - Sep 29, 2026 - Abstract #EP-0115; "The clinical success of peptide-conjugated radiopharmaceuticals, such as 68Ga/64Cu/177Lu-Dotatate, highlights the translational potential of this class of agents... AI-assisted de novo design enabled the development of CAIX-targeted peptide radiotracers for ccRCC imaging. Both candidates showed effective target binding and tumor localization in vivo, with the cyclic peptide demonstrating superior imaging performance. These results support the potential of AI-guided peptide discovery for CAIX-targeted imaging and theranostic development."
Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • CA9
|